Mol Med:褪黑激素可防止视黄酸诱导的骨质疏松症小鼠骨质破坏

2019-08-30 不详 网络

褪黑素对由视黄酸(RA)等药物诱导的骨质疏松症(OP)骨代谢失衡的保护作用尚不清楚。本研究旨在探讨褪黑素在基于小鼠模型的骨破坏中的作用。建立RA诱导的OP模型小鼠。为了评估褪黑激素对这些小鼠的影响,使用micro-CT来表征正常小鼠和用RA(模型),RA +低剂量褪黑激素(Mlt-L),RA +高剂量褪黑激素和(Mlt-H)和RA +阿仑膦酸钠(阳性对照)治疗的小鼠的骨小梁结构。还测量了骨小梁的形

褪黑素对由视黄酸(RA)等药物诱导的骨质疏松症(OP)骨代谢失衡的保护作用尚不清楚。本研究旨在探讨褪黑素在基于小鼠模型的骨破坏中的作用。

建立RA诱导的OP模型小鼠。为了评估褪黑激素对这些小鼠的影响,使用micro-CT来表征正常小鼠和用RA(模型),RA +低剂量褪黑激素(Mlt-L),RA +高剂量褪黑激素和(Mlt-H)和RA +阿仑膦酸钠(阳性对照)治疗的小鼠的骨小梁结构。还测量了骨小梁的形状,股骨头的长度和直径以及每组的椎骨的高度和直径(L1),并且通过抗酒石酸酸性磷酸酶(TRACP)染色测定破骨细胞的数量。同时,通过免疫组织化学测定评估碱性磷酸酶(ALP)的表达。还分析了各组之间在肝脏和肾脏氧化相关指标以及与骨代谢相关的血清和尿液指标方面的差异。此外,qRT-PCR和蛋白质印迹分别用于评估褪黑素对MC3T3-E1和RAW264.7细胞中成骨和破骨细胞分化的影响。

结果显示,RA诱导导致骨小梁的数量和密度减少,股骨的长度和直径减小和高度,椎骨直径(L1),骨量和密度的减少以及ALP的表达,以及破骨细胞数量增加。褪黑激素治疗减轻RA诱导的这些作用,增加OP小鼠的骨小梁数量,改善股骨和椎骨的微观结构(L1),增加骨量骨密度和ALP的表达,以及减少破骨细胞的数量。此外,血液和尿骨代谢相关指标显示褪黑激素促进骨形成并抑制骨吸收。测定小鼠肝脏和肾脏中的氧化剂和抗氧化剂生物标志物,发现褪黑激素促进了抗氧化剂水平并抑制了这些器官中氧化剂分子的水平。在体外,RA通过增加RAW264.7和MC3T3-E1细胞中的氧化应激水平来促进破骨细胞并抑制成骨,但褪黑激素逆转了这种作用。因此,褪黑激素可能在ERK / SMAD和NF-κB通路中发挥作用。

总之,该研究结果表明,褪黑激素可减轻RA诱导的OP模型小鼠的骨质流失,修复小梁微结构,促进骨形成。这些作用可能与通过ERK/SMAD和NF-κB通路降低体内和体外氧化水平有关。

原始出处:

Wang X, Liang T, et al., Melatonin prevents bone destruction in mice with retinoic acid-induced osteoporosis. Mol Med. 2019 Aug 28;25(1):43. doi: 10.1186/s10020-019-0107-0.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1928941, encodeId=3ed3192894177, content=<a href='/topic/show?id=d77590453d2' target=_blank style='color:#2F92EE;'>#褪黑激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90453, encryptionId=d77590453d2, topicName=褪黑激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Thu Jun 25 20:30:00 CST 2020, time=2020-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592589, encodeId=557b159258945, content=<a href='/topic/show?id=6dc2101853ed' target=_blank style='color:#2F92EE;'>#骨质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101853, encryptionId=6dc2101853ed, topicName=骨质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1d018108513, createdName=Eleven17, createdTime=Sun Sep 01 10:30:00 CST 2019, time=2019-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609971, encodeId=28aa16099e150, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Sep 01 10:30:00 CST 2019, time=2019-09-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1928941, encodeId=3ed3192894177, content=<a href='/topic/show?id=d77590453d2' target=_blank style='color:#2F92EE;'>#褪黑激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90453, encryptionId=d77590453d2, topicName=褪黑激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Thu Jun 25 20:30:00 CST 2020, time=2020-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592589, encodeId=557b159258945, content=<a href='/topic/show?id=6dc2101853ed' target=_blank style='color:#2F92EE;'>#骨质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101853, encryptionId=6dc2101853ed, topicName=骨质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1d018108513, createdName=Eleven17, createdTime=Sun Sep 01 10:30:00 CST 2019, time=2019-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609971, encodeId=28aa16099e150, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Sep 01 10:30:00 CST 2019, time=2019-09-01, status=1, ipAttribution=)]
    2019-09-01 Eleven17
  3. [GetPortalCommentsPageByObjectIdResponse(id=1928941, encodeId=3ed3192894177, content=<a href='/topic/show?id=d77590453d2' target=_blank style='color:#2F92EE;'>#褪黑激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90453, encryptionId=d77590453d2, topicName=褪黑激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Thu Jun 25 20:30:00 CST 2020, time=2020-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592589, encodeId=557b159258945, content=<a href='/topic/show?id=6dc2101853ed' target=_blank style='color:#2F92EE;'>#骨质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101853, encryptionId=6dc2101853ed, topicName=骨质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1d018108513, createdName=Eleven17, createdTime=Sun Sep 01 10:30:00 CST 2019, time=2019-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609971, encodeId=28aa16099e150, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Sep 01 10:30:00 CST 2019, time=2019-09-01, status=1, ipAttribution=)]